Autres langues Alimera Sciences, Inc.

Actions

ALIM

US0162592028

Temps réel estimé Cboe BZX Autres places de cotation 19:22:12 10/05/2024			Varia. 5j.	Varia. 1 janv.
3,54 ^USD	+4,73%		-2,88%	-17,94%

25/03	ALIMERA SCIENCES, INC. : Maxim toujours positif	ZM
19/03	Alimera Sciences, Inc. annonce que le premier patient a été randomisé dans le cadre de l'essai sur la rétinopathie radique mené par le réseau DRCR Retina.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences	07/05
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update	30/04
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20/03
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network	19/03
Alimera Sciences, Inc. Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network	19/03
Alimera Sciences: Q4 Earnings Snapshot	07/03
Alimera Sciences, Inc. Enters into the Seventh Amendment to Its Loan and Security Agreement	07/03
Earnings Flash (ALIM) ALIMERA SCIENCES Posts Q4 Revenue $26.3M	07/03
Earnings Flash (ALIM) ALIMERA SCIENCES Posts Q4 Revenue $26.3M	07/03
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results	07/03
Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024	07/03
Alimera Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Alimera Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
North American Morning Briefing : Powell Still in -2-	07/03
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update	29/02
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®	08/02
Alimera Completes Recruitment for the Synchronicity Study	04/01
Alimera Completes Recruitment for the Synchronicity Study	04/01
Alimera Sciences Appoints New CFO	02/01
Alimera Sciences, Inc. Names Elliot Maltz as Chief Financial Officer	02/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Alimera Sciences, Inc.

Actions

ALIM

US0162592028

Autres langues

Filtres